arGEN-X BV (NASDAQ:ARGX) – Analysts at SunTrust Banks issued their Q1 2018 earnings per share (EPS) estimates for arGEN-X BV in a research note issued on Monday, April 9th. SunTrust Banks analyst Y. Suneja forecasts that the company will post earnings of ($0.52) per share for the quarter. SunTrust Banks currently has a “Buy” rating and a $125.00 price target on the stock. SunTrust Banks also issued estimates for arGEN-X BV’s Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.59) EPS, Q4 2018 earnings at ($0.65) EPS, FY2018 earnings at ($2.31) EPS, FY2019 earnings at ($3.63) EPS, FY2020 earnings at ($3.69) EPS, FY2021 earnings at ($4.06) EPS and FY2022 earnings at ($3.06) EPS.
ARGX has been the subject of a number of other research reports. Zacks Investment Research downgraded arGEN-X BV from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Piper Jaffray raised their target price on arGEN-X BV to $100.00 and gave the company an “overweight” rating in a report on Tuesday, December 19th. Finally, JMP Securities raised their target price on arGEN-X BV from $74.00 to $87.00 and gave the company an “outperform” rating in a report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $86.00.
An institutional investor recently raised its position in arGEN-X BV stock. Alyeska Investment Group L.P. raised its holdings in arGEN-X BV (NASDAQ:ARGX) by 1.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 121,313 shares of the company’s stock after acquiring an additional 2,167 shares during the quarter. Alyeska Investment Group L.P. owned 0.45% of arGEN-X BV worth $2,743,000 as of its most recent filing with the SEC. 44.94% of the stock is owned by institutional investors.
WARNING: This piece was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://dakotafinancialnews.com/2018/04/12/brokers-offer-predictions-for-argen-x-bvs-q1-2018-earnings-argx.html.
arGEN-X BV Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.